Jonathan D. Akikusa

50 Flemington Rd
Parkville, VIC 3052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

Journal: Acta dermato-venereologica

Published: July 16, 2026

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

Journal: Acta dermato-venereologica

Published: July 16, 2026

The use of JAK inhibitors and tocilizumab in the management of TRAPS: a sibling case study.

The use of JAK inhibitors and tocilizumab in the management of TRAPS: a sibling case study.

Journal: Pediatric rheumatology online journal

Published: February 04, 2026

Clinical characteristics and outcomes of paediatric CNO: a retrospective cohort study with focus on zoledronic acid.

Clinical characteristics and outcomes of paediatric CNO: a retrospective cohort study with focus on zoledronic acid.

Journal: Rheumatology (Oxford, England)

Published: December 12, 2025

Development and validation of minimal disease activity, disease flare, and minimal clinically important difference for children with chronic nonbacterial osteomyelitis using a consensus and data-driven approach.

Development and validation of minimal disease activity, disease flare, and minimal clinically important difference for children with chronic nonbacterial osteomyelitis using a consensus and data-driven approach.

Journal: Annals of the rheumatic diseases

Published: December 04, 2025

Validation of Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Measures for Children With Chronic Nonbacterial Osteomyelitis.

Validation of Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Measures for Children With Chronic Nonbacterial Osteomyelitis.

Journal: Arthritis care & research

Published: November 20, 2025

Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.

Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.

Journal: Rheumatology (Oxford, England)

Published: July 24, 2025

Identifying domains for CNO and SAPHO: A scoping review to create domains from existing outcomes by the OMERACT CNO and SAPHO working group.

Identifying domains for CNO and SAPHO: A scoping review to create domains from existing outcomes by the OMERACT CNO and SAPHO working group.

Journal: Seminars in arthritis and rheumatism

Published: May 19, 2025

Disease modifying anti-rheumatic drug treatment cycles and rates of flare in juvenile idiopathic arthritis-a tale of Sisyphean endeavour?

Disease modifying anti-rheumatic drug treatment cycles and rates of flare in juvenile idiopathic arthritis-a tale of Sisyphean endeavour?

Journal: Rheumatology (Oxford, England)

Published: February 23, 2025

EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO).

EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO).

Journal: Annals of the rheumatic diseases

Published: September 11, 2024

EULAR/American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis.

EULAR/American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: September 11, 2024

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.

Journal: Annals of the rheumatic diseases

Published: October 03, 2023

Showing 1-12 of 56

Last Updated: 09/26/2026